Ceprotin Approval History
- FDA approved: Yes (First approved March 30th, 2007)
- Brand name: Ceprotin
- Generic name: protein C
- Dosage form: Injection
- Company: Baxter Healthcare Corporation
- Treatment for: Protein C Deficiency
Ceprotin is a plasma-derived Protein C concentrate for use as replacement therapy in patients with life-threatening blood-clotting complications related to severe congenital Protein C deficiency.
Development History and FDA Approval Process for Ceprotin
|Mar 30, 2007||Baxter Announces FDA Approval Of Ceprotin For Severe Congential Protein C Deficiency|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.